Sunitinib or Pazopanib: Is There Any Difference Between Tyrosine Kinase Inhibitors in the Pre-Nivolumab Setting in Metastatic Renal Cell Carcinoma?

Introduction Treatment options for metastatic renal cell carcinoma disease have been improved in recent years. However, there is still no optimal treatment sequence or combination for metastatic disease. We aimed to investigate whether patients differed in terms of disease outcomes regarding pre-niv...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cureus
Main Authors: Ucar, Gokhan, Acikgoz, Yusuf, Ergun, Yakup, Bal, Oznur, Yilmaz, Mesut, Karakaya, Serdar, Akdeniz, Nadiye, Kostek, Osman, Aydin Isak, Ozlem, Yazici Sener, Gorkem, Dirikoc, Merve, Aktürk Esen, Selin, Dogan, Mutlu, Uncu, Dogan
Formato: Artigo
Idioma:Inglês
Publicado: Cureus 2020
Assuntos:
Radiation Oncology
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7574822/
https://ncbi.nlm.nih.gov/pubmed/33094066
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7759/cureus.10525
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares